▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Todd Campbell

XMFEBCapital

@ebcapital

Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Recent Articles by Todd Campbell

businessman boxing GettyImages-496166842

Sep 20, 2017 by Todd Campbell

Pfizer and Johnson & Johnson's Brewing Brawl Gets Real

Pfizer has filed a suit against Johnson & Johnson alleging that it has engaged in anticompetitive behavior to block market demand for Pfizer's Remicade biosimilar.

lab scientists GettyImages-470913492

Sep 20, 2017 by Todd Campbell

Alnylam Notches a Game-Changing RNAi Win

Phase 3 trials of Alnylam's patisiran were a success, paving the way to an FDA filing for approval later this year.

ACA repeal GettyImages-681107422

Sep 19, 2017 by Todd Campbell

The GOP's Latest Strategy to Dismantle Obamacare Unveiled -- Here's What You Need to Know

A plan to shift health insurance to a block-grant program would give states the freedom to create their own insurance programs. But it may still fail to win support among moderate Republicans.

pharmacist_large getty

Sep 19, 2017 by Todd Campbell

Rite Aid (Finally!) Gets OK to Sell Stores to Walgreens

After agreeing to modifications, Walgreens can proceed with its plan to purchase nearly 2,000 Rite Aid stores.

market crash GettyImages-499578669

Sep 19, 2017 by Todd Campbell

Why Supernus Pharmaceuticals' Shares Plummeted 23.4% Today

A change to phase 3 trials evaluating its lead product candidate SPN-810 fueled investors' pessimism.

Genes GettyImages-645455760

Sep 19, 2017 by Todd Campbell

3 Innovation-Forward Healthcare Stocks to Buy Now

Illumina, Mazor Robotics, and Novocure are on the cutting edge of healthcare innovation. That could make them perfect stocks to own in growth portfolios.

lab scientists GettyImages-470913492

Sep 17, 2017 by Todd Campbell

Loxo Oncology's Up 230% in the Past Year -- Can You Still Make Money Buying It?

The company has plenty of cash on its balance sheet and a cancer drug that could soon make its way to the FDA, but you'll pay dearly to buy its shares.

hurricane damage 2 GettyImages-658126590

Sep 15, 2017 by Todd Campbell

Should I Buy Travelers Stock Despite Hurricanes Harvey And Irma?

Insurers will pay billions of dollars to repair damage caused by Hurricanes Harvey and Irma, but that may not be bad news for the long term.

money mountain GettyImages-89473514

Sep 15, 2017 by Todd Campbell, Dan Caplinger, and Demitri Kalogeropoulos

3 Stocks That Could Put Alibaba's Returns to Shame

HubSpot, Take-Two Interactive, and Weibo may offer investors a better shot at growth than Alibaba.

businessman boxing GettyImages-496166842

Sep 15, 2017 by Todd Campbell

Pfizer Punches Back at Johnson & Johnson in Prostate Cancer

The two companies are battling to expand the use of their cancer drugs in prostate-cancer patients.

pills on gold GettyImages-519336818

Sep 15, 2017 by Todd Campbell

3 Reasons Why Gilead Sciences Stock Is a Buy Now

A splashy acquisition that puts this company on the cutting edge of cancer treatment isn't the only reason to buy shares. Gilead Sciences' margins are among the best in biotech, and its valuation arguably makes it a bargain.

Sep 15, 2017 by Todd Campbell

How Much Does It Really Cost to Develop a Cancer Drug?

A new study concludes it costs $757 million to develop a new cancer drug, but is that the only reason why drugmakers charge sky-high drug prices or are other reasons to blame, too?

approval stamp GettyImages-483943680

Sep 14, 2017 by Todd Campbell

A Biosimilar Cure for Sky-High Cancer Drug Prices

The FDA has approved Amgen and Allergan's Mvasi, the first-ever cancer-drug biosimilar to win an OK.

market crash getty-images-sinking-stock-chart-woes_large

Sep 14, 2017 by Todd Campbell

Why Lexicon Pharmaceuticals Is Down 11% Today

Phase 3 data for its type 1 diabetes drug were published in a medical journal, and questions about safety risks could be crimping enthusiasm.

asthma GettyImages-107429791

Sep 13, 2017 by Todd Campbell

Regeneron's Dupixent Takes Another Step Toward Blockbuster Status

Dupixent's phase 3 trials in asthma were a success, clearing the way to an FDA filing this year in this multibillion-dollar indication.

money tree growing in jars GettyImages-49170429

Sep 12, 2017 by Todd Campbell

Warren Buffett Bags Quick 29% Return in Store Capital

After acquiring 10% of Store Capital in June, Berkshire Hathaway is already up nearly 30% in less than three months.

market crashing through the floor GettyImages-612737000

Sep 12, 2017 by Todd Campbell

Despite Assurances, Health Insurance Innovations Is Crashing 15% Today

Management yesterday responded to questions raised by short-sellers, but the response has failed to stabilize the company's stock price.

market crash image023 getty 1

Sep 11, 2017 by Todd Campbell

Why Health Insurance Innovations Dropped 21.9% Today

Short sellers are questioning the company's valuation, citing potential risks to its business.

businessman holding up a stop sign GettyImages-476226940

Sep 11, 2017 by Todd Campbell

Why Achillion Pharmaceuticals Crashed 22.2% Today

Johnson & Johnson is walking away from its agreement to develop Achillion Pharmaceuticals' hepatitis C drugs.

man with money falling getty-images-happy-retiree-raining-money_large

Sep 11, 2017 by Todd Campbell

Slash Your Medicare Drug Costs With These 6 Tips

Seniors are spending a lot of their money on medicine, and these tips can help reduce that spending by making sure you enroll in the best Medicare plan for you.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services